Type 1-polarized DC immunotherapeutic contains heterogeneous populations with IL-12p70 production restricted to a rare subset

Monocyte-derived DC therapies programmed for robust IL-12p70 production have been associated with favorable outcomes in cancer clinical trials. However, clinical responses remain inconsistent even under standardized protocols, and the cellular basis for this variability is unknown. We leveraged single-cell multiomics to characterize two widely used DC platforms, the high-IL-12p70-producing α-Type-1-polarized DC (αDC1) and the IL-12p70-deficient DC induced in the presence of PGE 2 (PGE 2 -DC), at baseline and following rhCD40L activation. DC generated from 7 healthy participants representing the spectrum of rhCD40L-induced IL-12p70 production were profiled by transcriptome analysis with 42-plex surface proteomics, multiplex ELISA, and ELISpot quantification of IL-12p70-producing cells. While αDC1 and PGE 2 -DC distinctly responded to rhCD40L, αDC1 alone comprised 3 transcriptionally and phenotypically distinct subpopulations in resting and stimulated states. Only a limited fraction of αDC1 coexpressed IL12A and IL12B (IL-12p70 producers), confirmed by ELISpot at the protein level. The distribution of αDC1 subclusters varied markedly between individuals and correlated with bulk cytokine and chemokine secretion profiles. Magnetic enrichment on the surface marker CD116 yielded αDC1 fractions that differentially primed naïve CD4 + T cells, demonstrating these subpopulations are functionally divergent and separable. This heterogeneity may underlie inconsistent clinical outcomes, providing a rationale for subcluster-based release criteria and patient stratification.

Authors

Institutions

Publication Details

Journal
JCI Insight
Published
2026-11-19
DOI
https://doi.org/10.1172/jci.insight.208466
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Type 1-polarized DC immunotherapeutic contains heterogeneous populations with IL-12p70 production restricted to a rare subset

Robbie B. Mailliard, Jeremy James Martinson, Bernard J. C. Macatangay, Paweł Kaliński et al.
JCI Insight
Immunotherapy and Immune Responses
article

Type 1-polarized DC immunotherapeutic contains heterogeneous populations with IL-12p70 production restricted to a rare subset

Robbie B. Mailliard, Jeremy James Martinson, Bernard J. C. Macatangay, Paweł Kaliński, Holly A. Bilben, Allison E. DePuyt, Charles R. Rinaldo, Peter E. J. Shoucair
article en

Abstract

Monocyte-derived DC therapies programmed for robust IL-12p70 production have been associated with favorable outcomes in cancer clinical trials. However, clinical responses remain inconsistent even under standardized protocols, and the cellular basis for this variability is unknown. We leveraged single-cell multiomics to characterize two widely used DC platforms, the high-IL-12p70-producing α-Type-1-polarized DC (αDC1) and the IL-12p70-deficient DC induced in the presence of PGE 2 (PGE 2 -DC), at baseline and following rhCD40L activation. DC generated from 7 healthy participants representing the spectrum of rhCD40L-induced IL-12p70 production were profiled by transcriptome analysis with 42-plex surface proteomics, multiplex ELISA, and ELISpot quantification of IL-12p70-producing cells. While αDC1 and PGE 2 -DC distinctly responded to rhCD40L, αDC1 alone comprised 3 transcriptionally and phenotypically distinct subpopulations in resting and stimulated states. Only a limited fraction of αDC1 coexpressed IL12A and IL12B (IL-12p70 producers), confirmed by ELISpot at the protein level. The distribution of αDC1 subclusters varied markedly between individuals and correlated with bulk cytokine and chemokine secretion profiles. Magnetic enrichment on the surface marker CD116 yielded αDC1 fractions that differentially primed naïve CD4 + T cells, demonstrating these subpopulations are functionally divergent and separable. This heterogeneity may underlie inconsistent clinical outcomes, providing a rationale for subcluster-based release criteria and patient stratification.

JCI Insight
University of Pittsburgh (US)
National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Office of the Director, National Institute of Allergy and Infectious Diseases
Good health and well-being
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon